Umbralisib - TG Therapeutics

Drug Profile

Umbralisib - TG Therapeutics

Alternative Names: RP 5307; RP-5264; TGR-1202

Latest Information Update: 07 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incozen Therapeutics; Rhizen Pharmaceuticals
  • Developer Columbia University Medical Center; TG Therapeutics Inc; Vanderbilt-Ingram Cancer Center
  • Class Antineoplastics; Benzopyrans; Pyrazoles; Pyrimidines; Small molecules
  • Mechanism of Action Casein kinase Iepsilon inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Waldenstrom's macroglobulinaemia
  • Phase I Myelofibrosis; Non-Hodgkin's lymphoma; Polycythaemia vera; Solid tumours
  • Research Multiple sclerosis
  • No development reported Hodgkin's disease; Mantle-cell lymphoma

Most Recent Events

  • 21 Feb 2018 Updated efficacy and adverse events data from a first-in-human phase I trial in haematological malignancies released by TG Therapeutics
  • 20 Feb 2018 TG Therapeutics completes a phase I trial in Haematological malignancies (Second-line therapy or greater, Late-stage disease, Monotherapy) in USA (PO) (NCT01767766)
  • 23 Jan 2018 Phase I development is ongoing in Non Hodgkin's lymphoma(Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top